Paper - WANFANG MED ONLINE

You Position: Home > Paper

Diagnosis and treatment of cholangiocarcinoma in era of precision medicine

( views:15, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 24

DOI:: 10.11569/wcjd.v25.i24.2167

Key Word:: 肝内胆管癌;肝门部胆管癌;远端胆管癌;分子变异;精准医疗;Intrahepatic cholangiocarcinoma;Perihilar cholangiocarcinoma;Distal cholangiocarcinoma;Molecular aberrations;Precision medicine

Abstract： Cholangiocarcinoma (CCA) is a kind of relatively rare biliary system malignant tumor that has an extremely poor prognosis due to the lack of understanding of the molecular pathogenesis and the shortage of effective therapeutic methods.The adoption of precision medicine and cancer genomic profiling enhance our understanding of tumor molecular pathogenesis and can help identify potential therapeutic targets.Research has identified significant differences between intrahepatic and extrahepatic CCA,including epidemiology,etiology,molecular mechanisms,therapeutic methods and prognosis.The first important step towards personalized precise medicine strategy is classification of CCA and identification of the unique characteristics of each subtype.Hopefully,the acquisition and integration of omics information of CCA subtypes,and based on this,the development of effective targeted therapy will improve the prognosis and overall survival of patients.

Reference

[1]Vincenzo Cardinale,Maria Consiglia Bragazzi,Guido Carpino,etc.Cholangiocarcinoma: increasing burden of classifications[J].2013,(5).
[2]Bardeesy, Nabeel,Mazzaferro, Vincenzo,Sia, Daniela,etc.Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma[J].2016,22(2).
[3]Nakamura, Hiromi,Arai, Yasuhito,Totoki, Yasushi,etc.Genomic spectra of biliary tract cancer[J].2015,47(9).
[4]Rizvi, Sumera,Gores, Gregory J..Emerging molecular therapeutic targets for cholangiocarcinoma[J].2017,67(3).
[5]Kawin Leelawat,Siriluck Narong,ee Udomchaiprasertkul,etc.Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells[J].2009,9(1).
[6]Shaib Y,El Serag HB.The epidemiology of cholangiocarcinoma.[J].2004,24(2).
[7]Sirica AE,Fingas CD,Guicciardi ME,etc.Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells.[J].2011,54(6).
[8]Reardon, Sara.Precision-medicine plan raises hopes[J].2015,517(Jan.29 TN.7536).
[9]Ross, Jeffrey S.,Stephens, Philip J.,Lipson, Doron,etc.Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets[J].2016,69(5).
[10]Sia, Daniela,Losic, Bojan,Moeini, Agrin,etc.Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma[J].2015,6(Jan.).
[11]Mitesh J, Borad,Mia D, Champion,Jan B, Egan,etc.Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.[J].2014,10(2).
[12]Terence G, Hall,Yi, Yu,Sudharshan, Eathiraj,etc.Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.[J].2016.
[13]Kerr,S.E.,Fritcher,E.G.B.,Zhang,J.,etc.Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions[J].2013,44(7).
[14]Arai,Y.,Totoki,Y.,Hosoda,F.,etc.Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma[J].2014,59(4).
[15]Graham,R.P.,BarrFritcher,E.G.,Pestova,E.,etc.Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma[J].2014,45(8).
[16]Sekiya,S.,Suzuki,A..Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes[J].2012,122(11).
[17]Collins, Francis S.,Varmus, Harold.A New Initiative on Precision Medicine[J].2015,372(9).
[18]Yachida, Shinichi,Wood, Laura D.,Suzuki, Masami,etc.Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma[J].2016,29(2).
[19]Ross,J.S.,Wang,K.,Gay,L.,etc.New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing[J].2014,19(3).
[20]Tait,P.,Thomas,H.C.,Thillainayagam,A.V.,etc.Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update[J].2012,61(12).
[21]Chaitanya R, Churi,Rachna, Shroff,Ying, Wang,etc.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.[J].2014,9.
[22]Ryohei, Nomura,Hiroaki, Fujii,Masaaki, Abe,etc.Mesothelin expression is a prognostic factor in cholangiocellular carcinoma.[J].1900,98(2).
[23]Vandecaveye,V.,Laleman,W.,VanSteenbergen,W.,etc.Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes[J].2012,55(6).
[24]Tan, Li,Wang, Jun,Tanizaki, Junko,etc.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors[J].2014,111(45).
[25]Bergquist, Annika,von Seth, Erik.Epidemiology of cholangiocarcinoma[J].2015,29(2).
[26]Kim,J.W.,Andersen,J.B.,Guan,K.-L.,etc.Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas[J].2013,32(25).
[27]Stuart Duncan, Morton,Massimiliano, Cadamuro,Simone, Brivio,etc.Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.[J].2015,6.